DOJ Moves Forward on Cannabis Rescheduling Following Trump Order
Justice Department advances federal marijuana rescheduling process, delivering on Trump administration directive issued months earlier.
The Department of Justice has officially announced its move to advance federal marijuana rescheduling, fulfilling a directive issued by the Trump administration several months ago. This development marks a concrete step forward in what has been a prolonged federal review process that began under the previous administration, with the DOJ now taking active measures to implement the executive guidance.
The rescheduling announcement carries substantial implications for cannabis operators across multiple market segments. Multi-state operators currently face the punitive 280E tax provision, which prevents standard business deductions and creates effective tax rates exceeding 70% in many cases. A move from Schedule I to Schedule III would eliminate this burden, potentially boosting EBITDA margins by 20-40 percentage points for major players like Curaleaf, Green Thumb Industries, and Trulieve.
Federal rescheduling also opens pathways for institutional capital that has remained largely sidelined due to cannabis's current Schedule I classification. Banks, pension funds, and traditional investment firms have avoided the sector due to federal illegality concerns, despite state-level legalization spanning 38 states. The regulatory shift could unlock billions in institutional investment while enabling standard banking services that have forced operators to rely on expensive alternative financing.
The timing aligns with broader industry consolidation trends as operators seek scale advantages amid compressed margins and market saturation in key states. California's wholesale prices have declined over 60% since 2021, while New York's adult-use rollout faces ongoing regulatory delays. Federal rescheduling provides a potential catalyst for sector recovery, particularly for companies with strong balance sheets positioned to benefit from improved tax treatment and expanded access to capital markets.
While the DOJ announcement represents progress, the rescheduling process still requires completion of formal regulatory procedures through the Drug Enforcement Administration. The cannabis sector has experienced multiple false starts on federal reform, making investor sentiment cautious despite the positive development. However, the Trump administration's direct involvement suggests stronger political backing than previous efforts, potentially accelerating the timeline for implementation and providing the regulatory clarity that has eluded the industry for years.